DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184

Lupus. 2015 May;24(6):648-9. doi: 10.1177/0961203315573347. Epub 2015 Feb 27.

Authors

R F van Vollenhoven¹, M Layton², L Kahl³, L Schifano⁴, E Hachulla⁵, D Machado⁶, D Staumont-Sallé⁵, J Patel³; JAK115919 Study Team

Affiliations

¹ Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden [email protected].
² GlaxoSmithKline, Stevenage, Hertfordshire, UK.
³ GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, UK.
⁴ GlaxoSmithKline, Research Triangle Park, NC, USA.
⁵ Claude Huriez Hospital, University of Lille, Lille, France.
⁶ CAICI Institute, Rosario, Santa Fe, Argentina.

PMID: 25724932
DOI: 10.1177/0961203315573347

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Azetidines / administration & dosage
Azetidines / adverse effects*
Chemical and Drug Induced Liver Injury / enzymology
Chemical and Drug Induced Liver Injury / etiology*
Drug Hypersensitivity Syndrome / enzymology
Drug Hypersensitivity Syndrome / etiology*
Female
Humans
Janus Kinase 1 / antagonists & inhibitors
Lupus Erythematosus, Systemic / drug therapy*
Lupus Erythematosus, Systemic / enzymology
Lupus Erythematosus, Systemic / physiopathology
Middle Aged
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Randomized Controlled Trials as Topic
Triazoles / administration & dosage
Triazoles / adverse effects*

Substances

Azetidines
GSK2586184
Protein Kinase Inhibitors
Triazoles
Janus Kinase 1